Copyright
©The Author(s) 2024.
World J Clin Oncol. May 24, 2024; 15(5): 635-643
Published online May 24, 2024. doi: 10.5306/wjco.v15.i5.635
Published online May 24, 2024. doi: 10.5306/wjco.v15.i5.635
Group A (N = 42) | Group B (N = 21) | P value | |||
n (%) | 95%CI | n (%) | 95%CI | ||
Best overall response | |||||
Complete response (CR) | 0 | - | 0 | - | - |
Partial response (PR) | 30 (71.4) | - | 9 (42.9) | - | - |
Stable disease (SD) | 12 (28.6) | - | 10 (47.6) | - | - |
Progressive disease | 0 (0) | - | 2 (9.5) | - | - |
Overall response rate (CR + PR) | 30 (71.4) | 55.4-84.3 | 9 (42.9) | 21.8-66.0 | 0.03 |
Disease control rate (CR + PR + SD) | 42 (100) | 91.6-1.00 | 19 (90.5) | 69.6-98.8 | 2.527e-13 |
- Citation: Ma XT, Ou K, Yang WW, Cao BY, Yang L. Human epidermal growth factor receptor 2 expression level and combined positive score can evaluate efficacy of advanced gastric cancer. World J Clin Oncol 2024; 15(5): 635-643
- URL: https://www.wjgnet.com/2218-4333/full/v15/i5/635.htm
- DOI: https://dx.doi.org/10.5306/wjco.v15.i5.635